Study: NCT02879409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral: 100 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral: 100 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 5mg once daily increasing to 10mg once daily as required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 5mg once daily increasing to 10mg once daily as required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human insulin
Description: insulin dosage and administration according to physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human insulin
Description: insulin dosage and administration according to physician